129 results on '"Weiler JM"'
Search Results
2. National Athletic Trainers' Association position statement: management of asthma in athletes.
- Author
-
Miller MG, Weiler JM, Baker R, Collins J, and D'Alonzo G
- Abstract
Objective: To present guidelines for the recognition, prophylaxis, and management of asthma that lead to improvement in the quality of care certified athletic trainers and other health care providers can offer to athletes with asthma, especially exercise-induced asthma.Background: Many athletes have difficulty breathing during or after athletic events and practices. Although a wide variety of conditions can predispose an athlete to breathing difficulties, the most common cause is undiagnosed or uncontrolled asthma. At least 15% to 25% of athletes may have signs and symptoms suggestive of asthma, including exercise-induced asthma. Athletic trainers are in a unique position to recognize breathing difficulties caused by undiagnosed or uncontrolled asthma, particularly when asthma follows exercise. Once the diagnosis of asthma is made, the athletic trainer should play a pivotal role in supervising therapies to prevent and control asthma symptoms. It is also important for the athletic trainer to recognize when asthma is not the underlying cause for respiratory difficulties, so that the athlete can be evaluated and treated properly.Recommendations: The recommendations contained in this position statement describe a structured approach for the diagnosis and management of asthma in an exercising population. Athletic trainers should be educated to recognize asthma symptoms in order to identify patients who might benefit from better management and should understand the management of asthma, especially exercise-induced asthma, to participate as active members of the asthma care team. [ABSTRACT FROM AUTHOR]
- Published
- 2005
3. Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator.
- Author
-
Weiler JM, Bloomfield JR, Woodworth GG, Grant AR, Layton TA, Brown TL, McKenzie DR, Baker TW, Watson GS, Weiler, J M, Bloomfield, J R, Woodworth, G G, Grant, A R, Layton, T A, Brown, T L, McKenzie, D R, Baker, T W, and Watson, G S
- Abstract
Background: Sedating antihistamines may impair driving performance as seriously as alcohol.Objective: To compare the effects of fexofenadine, diphenhydramine, alcohol, and placebo on driving performance.Design: Randomized, double-blind, double-dummy, four-treatment, four-period crossover trial.Setting: The Iowa Driving Simulator.Participants: 40 licensed drivers with seasonal allergic rhinitis who were 25 to 44 years of age.Intervention: One dose of fexofenadine (60 mg), diphenhydramine (50 mg), alcohol (approximately 0.1% blood alcohol concentration), or placebo, given at weekly intervals before participants drove for 1 hour in the Iowa Driving Simulator.Measurements: The primary end point was coherence, a continuous measure of participants' ability to match the varying speed of a vehicle that they were following. Secondary end points were drowsiness and other driving measures, including lane keeping and response to a vehicle that unexpectedly blocked the lane ahead.Results: Participants had significantly better coherence after taking alcohol or fexofenadine than after taking diphenhydramine. Lane keeping (steering instability and crossing the center line) was impaired after alcohol and diphenhydramine use compared with fexofenadine use. Mean response time to the blocking vehicle was slowest after alcohol use (2.21 seconds) compared with fexofenadine use (1.95 seconds). Self-reported drowsiness did not predict lack of coherence and was weakly associated with minimum following distance, steering instability, and leftlane excursion.Conclusions: Participants had similar performance when treated with fexofenadine or placebo. After alcohol use, participants performed the primary task well but not the secondary tasks; as a result, overall driving performance was poorer. After participants took diphenhydramine, driving performance was poorest, indicating that diphenhydramine had a greater impact on driving than alcohol did. Drowsiness ratings were not a good predictor of impairment, suggesting that drivers cannot use drowsiness to indicate when they should not drive. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
4. Drug Effects on Driving Performance.
- Author
-
Weiler, JM, Woodworth, G, and Watson, G
- Published
- 2000
- Full Text
- View/download PDF
5. Exercise-induced hypersensitivity syndromes in recreational and competitive athletes: a PRACTALL consensus report (what the general practitioner should know about sports and allergy)
- Author
-
William R. Henderson, Timothy J. Craig, K-H. Carlsen, Tari Haahtela, Luís Delgado, Marta Ferrer, F Drobnic, Nikolaos G. Papadopoulos, Jan Lötvall, C C Randolph, André Moreira, R. G. Van Wijk, Antonino Romano, Lawrence B. Schwartz, Thomas B. Casale, S. Del Giacco, John M. Weiler, Sergio Bonini, Elliot Israel, Plastic and Reconstructive Surgery and Hand Surgery, Internal Medicine, Schwartz, Lb, Delgado, L, Craig, T, Bonini, Sergio, Carlsen, Kh, Casale, Tb, DEL GIACCO, S, Drobnic, F, VAN WIJK, Rg, Ferrer, M, Haahtela, T, Henderson, Wr, Israel, E, Lötvall, J, Moreira, A, Papadopoulos, Ng, Randolph, Cc, Romano, A, and Weiler, Jm
- Subjects
medicine.medical_specialty ,Allergy ,Urticaria ,Immunology ,MEDLINE ,Physical exercise ,Competitive athletes ,Hypersensitivity ,medicine ,Humans ,Immunology and Allergy ,Anaphylaxis ,Exercise ,Recreation ,Rhinitis ,Asthma ,biology ,business.industry ,Athletes ,Syndrome ,medicine.disease ,biology.organism_classification ,Surgery ,Asthma, Exercise-Induced ,Family medicine ,business - Abstract
Exercise-induced (EI) hypersensitivity disorders are significant problems for both recreational and competitive athletes. These include EI-asthma, EI-bronchoconstriction, EI-rhinitis, EI-anaphylaxis and EI-urticaria. A group of experts from the European Academy of Allergology and Clinical Immunology and the American Academy of Allergy Asthma and Immunology met to discuss the pathogenesis of these disorders and how to diagnose and treat them, and then to develop a consensus report. Key words (exercise with asthma, bronchoconstriction, rhinitis, urticaria or anaphylaxis) were used to search Medline, the Cochrane database and related websites through February 2008 to obtain pertinent information which, along with personal reference databases and institutional experience with these disorders, were used to develop this report. The goal is to provide physicians with guidance in the diagnosis, understanding and management of EI-hypersensitivity disorders to enable their patients to safely return to exercise-related activities.
- Published
- 2008
6. How Participating in Sports Causes Manifestations and Mimics of Allergic Conditions and What to Do About Them for Optimum Performance.
- Author
-
Weiler JM and Greenberger PA
- Subjects
- Humans, Surveys and Questionnaires, Hypersensitivity diagnosis, Sports
- Published
- 2020
- Full Text
- View/download PDF
7. Special Considerations and Perspectives for Exercise-Induced Bronchoconstriction (EIB) in Olympic and Other Elite Athletes.
- Author
-
Zeiger JS and Weiler JM
- Subjects
- Athletes, Bronchoconstriction, Humans, Asthma, Asthma, Exercise-Induced diagnosis, Asthma, Exercise-Induced therapy, Sports
- Abstract
Diagnosing and treating elite and Olympic athletes with exercise-induced bronchoconstriction has been well established. However, a subset of elite and Olympic athletes with exercise-induced bronchoconstriction experience symptoms of breathlessness due to lack of adherence, improper medications, and/or generalized breathing dysfunction. A short review of traditional treatment plans for elite and Olympic athletes is presented along with the challenges of adherence, managing dysfunctional breathing, and measuring and treating mental skills deficits that may impact breathing. Elite and Olympic athletes may not respond to traditional treatment for exercise-induced bronchospasm, and we present some of the reasons why the athletes fail to respond. Furthermore, we present information on how to detect and treat elite and Olympic athletes with difficult-to-treat asthma. As part of this review we developed a flow diagram for medical providers to identify the reasons for lack of response to traditional treatment plans for exercise-induced bronchoconstriction with options for other treatment modalities., (Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
8. Fluticasone furoate/vilanterol versus fluticasone propionate in patients with asthma and exercise-induced bronchoconstriction.
- Author
-
Martin N, Weiler JM, Pearlman D, Jacques L, Nunn C, Forth R, West S, Dunn K, and O'Byrne PM
- Subjects
- Administration, Inhalation, Adolescent, Adult, Asthma, Exercise-Induced diagnosis, Asthma, Exercise-Induced physiopathology, Bronchoconstriction physiology, Child, Cross-Over Studies, Double-Blind Method, Drug Administration Schedule, Drug Combinations, Exercise physiology, Female, Forced Expiratory Volume, Humans, Male, Middle Aged, Treatment Outcome, Young Adult, Androstadienes administration & dosage, Asthma, Exercise-Induced drug therapy, Benzyl Alcohols administration & dosage, Bronchoconstriction drug effects, Chlorobenzenes administration & dosage, Fluticasone administration & dosage
- Abstract
Objective : To investigate whether once-daily (OD) fluticasone furoate (FF)/vilanterol (VI) provides greater long-term protection from postexercise fall in forced expiratory volume in 1 s (FEV
1 ) than twice-daily (BD) fluticasone propionate (FP) in patients with asthma and exercise-induced bronchoconstriction. Methods : A randomized, double-blind, crossover study was conducted in patients (aged 12-50 years) on low-/mid-dose maintenance inhaled corticosteroid. Following a 4-week run-in period (FP 250 µg BD), patients with a ≥ 20% decrease in postexercise FEV1 received FF/VI 100/25 µg OD or FP 250 µg BD for 2 weeks. Exercise challenges were carried out 23 h after the first dose of study medication, and 12 and 23 h after evening clinic dose at the end of the 2-week treatment period. After a 2-week washout period (FP 250 µg), patients crossed over treatments, with procedures and tests repeated. The primary endpoint was mean maximal percentage decrease from pre-exercise FEV1 following exercise challenge 12-h postevening dose on Day 14. Results: The mean maximal percentage decrease from pre-exercise FEV1 after the 12-h exercise challenge (Day 14) was 15.02% with FF/VI, and 16.71% with FP (difference, -1.69; 95% confidence interval, -3.76 to 0.39; p = 0.109). After the 23-h exercise challenge (Day 14), respective mean maximal decreases were 11.90% and 14.05% (difference, -2.15; 95% confidence interval, -4.31 to 0.01). Conclusion: The study failed to show a difference between FF/VI and FP at providing long-term protection from exercise-induced bronchoconstriction.- Published
- 2020
- Full Text
- View/download PDF
9. Randomized, Double-Blind, Crossover, Clinical-End-Point Pilot Study to Examine the Use of Exhaled Nitric Oxide as a Bioassay for Dose Separation of Inhaled Fluticasone Propionate.
- Author
-
Weiler JM, Sorkness CA, Hendeles L, Nichols S, and Zhu Y
- Subjects
- Administration, Inhalation, Adolescent, Adult, Aged, Asthma physiopathology, Biological Assay, Breath Tests, Cross-Over Studies, Double-Blind Method, Female, Forced Expiratory Volume, Humans, Male, Middle Aged, Pilot Projects, Young Adult, Anti-Asthmatic Agents pharmacology, Asthma metabolism, Fluticasone-Salmeterol Drug Combination pharmacology, Glucocorticoids pharmacology, Nitric Oxide metabolism
- Abstract
This was a randomized, double-blind, crossover, clinical-end-point pilot study examining the hypothesis that inhaled fluticasone propionate decreases exhaled nitric oxide (eNO) concentrations within a week of beginning treatment and shows evidence of dose separation across the marketed dose range. Subjects had a ≥6-month history of asthma and screening eNO ≥60 parts per billion. At the start of each treatment period, eNO was ≥55 parts per billion, and forced expiratory volume in 1 second was ≥50% predicted. Subjects attended a clinic visit daily on consecutive mornings during each of 3 1-week treatment periods to measure eNO and receive once-daily doses of 100/50, 250/50, or 500/50 fluticasone propionate/salmeterol combination product (Advair
® Diskus). Daily eNO value recorded was the highest of 3 measurements; 1 inhalation of treatment was then administered. Procedures were repeated for 3 treatment cycles, separated by 14-day minimum washouts. A total of 105 subjects were screened; 22 were randomized; and 17 completed all treatments. Mean percentage eNO decrease (standard deviation) from day 1 baseline for each treatment period was 36.6 (±18.7), 45.3 (±16.5), and 54.6 (±12.5) with Advair® 100/50, 250/50, and 500/50, respectively. Mean percentage decrease in eNO across each treatment (dose) was modeled using a mixed-model ANOVA. Although the overall treatment was significant (P = .0015), because of the relatively small sample size and within-subject variability, only the 100/50 vs 500/50 (P = .0003) and 250/50 vs 500/50 (P = .047) treatments were significantly different., (© 2017, The American College of Clinical Pharmacology.)- Published
- 2018
- Full Text
- View/download PDF
10. Exercise-induced bronchoconstriction update-2016.
- Author
-
Weiler JM, Brannan JD, Randolph CC, Hallstrand TS, Parsons J, Silvers W, Storms W, Zeiger J, Bernstein DI, Blessing-Moore J, Greenhawt M, Khan D, Lang D, Nicklas RA, Oppenheimer J, Portnoy JM, Schuller DE, Tilles SA, and Wallace D
- Subjects
- Humans, Asthma, Exercise-Induced diagnosis, Asthma, Exercise-Induced epidemiology, Asthma, Exercise-Induced physiopathology, Asthma, Exercise-Induced therapy, Bronchoconstriction
- Abstract
The first practice parameter on exercise-induced bronchoconstriction (EIB) was published in 2010. This updated practice parameter was prepared 5 years later. In the ensuing years, there has been increased understanding of the pathogenesis of EIB and improved diagnosis of this disorder by using objective testing. At the time of this publication, observations included the following: dry powder mannitol for inhalation as a bronchial provocation test is FDA approved however not currently available in the United States; if baseline pulmonary function test results are normal to near normal (before and after bronchodilator) in a person with suspected EIB, then further testing should be performed by using standardized exercise challenge or eucapnic voluntary hyperpnea (EVH); and the efficacy of nonpharmaceutical interventions (omega-3 fatty acids) has been challenged. The workgroup preparing this practice parameter updated contemporary practice guidelines based on a current systematic literature review. The group obtained supplementary literature and consensus expert opinions when the published literature was insufficient. A search of the medical literature on PubMed was conducted, and search terms included pathogenesis, diagnosis, differential diagnosis, and therapy (both pharmaceutical and nonpharmaceutical) of exercise-induced bronchoconstriction or exercise-induced asthma (which is no longer a preferred term); asthma; and exercise and asthma. References assessed as relevant to the topic were evaluated to search for additional relevant references. Published clinical studies were appraised by category of evidence and used to document the strength of the recommendation. The parameter was then evaluated by Joint Task Force reviewers and then by reviewers assigned by the parent organizations, as well as the general membership. Based on this process, the parameter can be characterized as an evidence- and consensus-based document., (Copyright © 2016 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
11. A World Allergy Organization international survey on physical activity as a treatment option for asthma and allergies.
- Author
-
Moreira A, Bonini M, Pawankar R, Anderson SD, Carlsen KH, Randolph C, Silvers W, Storms W, Weiler JM, and Bonini S
- Abstract
Background: Physical exercise has been shown to improve asthma symptoms, QoL, exercise capacity, bronchial hyperresponsiveness and lung function and is recommended as a supplementary treatment to pharmacotherapy for asthma. Clinicians are well placed to promote physically active lifestyles, but their role and practice towards promoting physically active lifestyles among patients has not been fully investigated. This study was designed to investigate the knowledge, propensity, attitude and practices of clinicians towards the promotion of physical activity among patients with asthma and allergies., Methods: Two hundred and eighty clinicians (mean age; 46 ± 13 years; with a clinical experience of practice for 15 ± 7 years) participated in a global survey. The survey comprised a 29-item questionnaire, which gathered information on attitudes of the clinicians towards promoting physical activity, their knowledge and their beliefs regarding evidence for benefits of physical activity as a supplementary treatment in patients with asthma and allergies., Results: Almost all respondents were aware of the strong evidence in favor of physical activity for the psychological well-being, weight control, decreased risk of diabetes, ischemic heart disease and arterial hypertension. Evidence for reduction in the risk for developing asthma and for better asthma control were reported by 60.0% and 85.4% of participants, respectively. The majority (85.0%) of clinicians strongly agreed that promoting physical activity is important to health care, although 95.5% considered they required more educational training. Although two thirds of them usually recommended exercise to their asthmatic/allergic patients, only 24.0% reported having previous training on the subject of such counseling. Almost all believed that effective counseling about a healthy diet, exercise and weight management would be easier if the clinician himself/herself was physically fit and healthy., Conclusions: The results of this global survey indicate that clinicians working in the field of allergy and respiratory diseases are well aware of the evidence supporting the benefits of physical activity for asthma and allergic diseases although they need more training in such counseling. Therefore, concerted efforts are needed towards educating clinicians towards promoting physical activity and weight management, as a supplementary treatment for asthma and allergies.
- Published
- 2014
- Full Text
- View/download PDF
12. Improving screening and diagnosis of exercise-induced bronchoconstriction: a call to action.
- Author
-
Weiler JM, Hallstrand TS, Parsons JP, Randolph C, Silvers WS, Storms WW, and Bronstone A
- Subjects
- Asthma, Exercise-Induced complications, Asthma, Exercise-Induced diagnosis, Asthma, Exercise-Induced etiology, Bronchial Diseases complications, Humans, Reproducibility of Results, Sensitivity and Specificity, Bronchial Diseases diagnosis, Bronchial Diseases etiology, Bronchoconstriction physiology, Exercise, Surveys and Questionnaires standards
- Abstract
This article summarizes the findings of an expert panel of nationally recognized allergists and pulmonologists who met to discuss how to improve detection and diagnosis of exercise-induced bronchoconstriction (EIB), a transient airway narrowing that occurs during and most often after exercise in people with and without underlying asthma. EIB is both commonly underdiagnosed and overdiagnosed. EIB underdiagnosis may result in habitual avoidance of sports and physical activity, chronic deconditioning, weight gain, poor asthma control, low self-esteem, and reduced quality of life. Routine use of a reliable and valid self-administered EIB screening questionnaire by professionals best positioned to screen large numbers of people could substantially improve the detection of EIB. The authors conducted a systematic review of the literature that evaluated the accuracy of EIB screening questionnaires that might be adopted for widespread EIB screening in the general population. Results of this review indicated that no existing EIB screening questionnaire had adequate sensitivity and specificity for this purpose. The authors present a call to action to develop a new EIB screening questionnaire, and discuss the rigorous qualitative and quantitative research necessary to develop and validate such an instrument, including key methodological pitfalls that must be avoided., (Copyright © 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
13. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction.
- Author
-
Parsons JP, Hallstrand TS, Mastronarde JG, Kaminsky DA, Rundell KW, Hull JH, Storms WW, Weiler JM, Cheek FM, Wilson KC, and Anderson SD
- Subjects
- Administration, Inhalation, Evidence-Based Medicine, Humans, Adrenergic beta-Agonists therapeutic use, Anti-Asthmatic Agents therapeutic use, Asthma, Exercise-Induced diagnosis, Asthma, Exercise-Induced drug therapy, Asthma, Exercise-Induced prevention & control, Leukotriene Antagonists therapeutic use
- Abstract
Background: Exercise-induced bronchoconstriction (EIB) describes acute airway narrowing that occurs as a result of exercise. EIB occurs in a substantial proportion of patients with asthma, but may also occur in individuals without known asthma., Methods: To provide clinicians with practical guidance, a multidisciplinary panel of stakeholders was convened to review the pathogenesis of EIB and to develop evidence-based guidelines for the diagnosis and treatment of EIB. The evidence was appraised and recommendations were formulated using the Grading of Recommendations, Assessment, Development, and Evaluation approach., Results: Recommendations for the treatment of EIB were developed. The quality of evidence supporting the recommendations was variable, ranging from low to high. A strong recommendation was made for using a short-acting β(2)-agonist before exercise in all patients with EIB. For patients who continue to have symptoms of EIB despite the administration of a short-acting β(2)-agonist before exercise, strong recommendations were made for a daily inhaled corticosteroid, a daily leukotriene receptor antagonist, or a mast cell stabilizing agent before exercise., Conclusions: The recommendations in this Guideline reflect the currently available evidence. New clinical research data will necessitate a revision and update in the future.
- Published
- 2013
- Full Text
- View/download PDF
14. Reproducibility of the airway response to an exercise protocol standardized for intensity, duration, and inspired air conditions, in subjects with symptoms suggestive of asthma.
- Author
-
Anderson SD, Pearlman DS, Rundell KW, Perry CP, Boushey H, Sorkness CA, Nichols S, and Weiler JM
- Subjects
- Adolescent, Adult, Asthma diagnosis, Asthma physiopathology, Child, Female, Humans, Male, Middle Aged, Reproducibility of Results, Surveys and Questionnaires, Time Factors, Young Adult, Asthma, Exercise-Induced diagnosis, Asthma, Exercise-Induced physiopathology, Bronchoconstriction physiology, Exercise Test methods, Inhalation physiology
- Abstract
Background: Exercise testing to aid diagnosis of exercise-induced bronchoconstriction (EIB) is commonly performed. Reproducibility of the airway response to a standardized exercise protocol has not been reported in subjects being evaluated with mild symptoms suggestive of asthma but without a definite diagnosis. This study examined reproducibility of % fall in FEV1 and area under the FEV1 time curve for 30 minutes in response to two exercise tests performed with the same intensity and duration of exercise, and inspired air conditions., Methods: Subjects with mild symptoms of asthma exercised twice within approximately 4 days by running for 8 minutes on a motorized treadmill breathing dry air at an intensity to induce a heart rate between 80-90% predicted maximum; reproducibility of the airway response was expressed as the 95% probability interval., Results: Of 373 subjects challenged twice 161 were positive (≥ 10% fall FEV1 on at least one challenge). The EIB was mild and 77% of subjects had <15% fall on both challenges. Agreement between results was 76.1% with 56.8% (212) negative (< 10% fall FEV1) and 19.3% (72) positive on both challenges. The remaining 23.9% of subjects had only one positive test. The 95% probability interval for reproducibility of the % fall in FEV1 and AUC0-30 min was ± 9.7% and ± 251% for all 278 adults and ± 13.4% and ± 279% for all 95 children. The 95% probability interval for reproducibility of % fall in FEV1 and AUC0-30 min for the 72 subjects with two tests ≥ 10% fall FEV1 was ± 14.6% and ± 373% and for the 34 subjects with two tests ≥ 15% fall FEV1 it was ± 12.2% and ± 411%. Heart rate and estimated ventilation achieved were not significantly different either on the two test days or when one test result was positive and one was negative., Conclusions: Under standardized, well controlled conditions for exercise challenge, the majority of subjects with mild symptoms of asthma demonstrated agreement in test results. Performing two tests may need to be considered when using exercise to exclude or diagnose EIB, when prescribing prophylactic treatment to prevent EIB and when designing protocols for clinical trials.
- Published
- 2010
- Full Text
- View/download PDF
15. Safety of binodenoson, a selective adenosine A2A receptor agonist vasodilator pharmacological stress agent, in healthy subjects with mild intermittent asthma.
- Author
-
Murray JJ, Weiler JM, Schwartz LB, Busse WW, Katial RK, Lockey RF, McFadden ER Jr, Pixton GC, and Barrett RJ
- Subjects
- Adenosine administration & dosage, Adenosine adverse effects, Adenosine therapeutic use, Adolescent, Adult, Analysis of Variance, Asthma physiopathology, Dose-Response Relationship, Drug, Double-Blind Method, Exercise Test, Female, Humans, Male, Middle Aged, Placebos, Respiratory Function Tests, Single-Blind Method, Treatment Outcome, Vasodilator Agents administration & dosage, Vasodilator Agents adverse effects, Adenosine analogs & derivatives, Asthma complications, Vasodilator Agents therapeutic use
- Abstract
Background: The pharmacological stress agents adenosine and dipyridamole are contraindicated in asthma patients because of the risk of adenosine receptor-mediated bronchospasm. Binodenoson, a selective adenosine A(2A) receptor agonist, produces maximal coronary hyperemia during pharmacological stress testing yet has a low affinity for the adenosine A(1), A(2B), and A(3) receptors that are probably responsible for bronchospasm. This study was conducted to assess the safety of binodenoson in 87 healthy young adult volunteers with documented mild, intermittent asthma., Methods and Results: This study consisted of a dose-escalating, single-blinded phase and a placebo-controlled, double-blinded phase conducted in healthy, young adults with documented mild, intermittent, asthma. In the single-blinded phase, 3 sequential cohorts of 8 subjects received intravenous binodenoson (0.5, 1.0, and 1.5 microg/kg). In the double-blinded phase, commenced after medical review of results from the single-blinded phase, subjects were randomly assigned 2:1 to either binodenoson 1.5 microg/kg (n=41) or placebo (n=22). The primary end point was clinically significant bronchoconstriction, defined as a decrease in forced expiratory volume in 1 second of >/=20% from the preinjection measure. Secondary safety end points were changes from preinjection measure in forced expiratory volume in 1 second, forced vital capacity, and forced expiratory flow during the middle 50% of the forced vital capacity; vital signs; pulse oximetry; and adverse events. Binodenoson caused no clinically significant bronchoconstriction or alterations in pulmonary function parameters and transiently increased heart rate and systolic blood pressure. The most common treatment-emergent adverse events were tachycardia, dizziness, and flushing., Conclusions: Binodenoson was safe, well tolerated, and caused no clinically significant bronchoconstriction or pulmonary responses in a small population of healthy subjects with mild, intermittent asthma.
- Published
- 2009
- Full Text
- View/download PDF
16. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma.
- Author
-
Anderson SD, Charlton B, Weiler JM, Nichols S, Spector SL, and Pearlman DS
- Subjects
- Adolescent, Adult, Asthma physiopathology, Bronchial Hyperreactivity physiopathology, Child, Female, Forced Expiratory Volume, Humans, Male, Middle Aged, Predictive Value of Tests, Sensitivity and Specificity, United States, Young Adult, Asthma diagnosis, Bronchial Hyperreactivity diagnosis, Bronchial Provocation Tests methods, Bronchoconstriction drug effects, Bronchoconstrictor Agents, Exercise Test, Mannitol, Methacholine Chloride
- Abstract
Background: Asthma can be difficult to diagnose, but bronchial provocation with methacholine, exercise or mannitol is helpful when used to identify bronchial hyperresponsiveness (BHR), a key feature of the disease. The utility of these tests in subjects with signs and symptoms of asthma but without a clear diagnosis has not been investigated. We investigated the sensitivity and specificity of mannitol to identify exercise-induced bronchoconstriction (EIB) as a manifestation of BHR; compared this with methacholine; and compared the sensitivity and specificity of mannitol and methacholine for a clinician diagnosis of asthma., Methods: 509 people (6-50 yr) were enrolled, 78% were atopic, median FEV1 92.5% predicted, and a low NAEPPII asthma score of 1.2. Subjects with symptoms of seasonal allergy were excluded. BHR to exercise was defined as a > or = 10% fall in FEV1 on at least one of two tests, to methacholine a PC20 < or = 16 mg/ml and to mannitol a 15% fall in FEV1 at < or = 635 mg or a 10% fall between doses. The clinician diagnosis of asthma was made on examination, history, skin tests, questionnaire and response to exercise but they were blind to the mannitol and methacholine results., Results: Mannitol and methacholine were therapeutically equivalent to identify EIB, a clinician diagnosis of asthma, and prevalence of BHR. The sensitivity/specificity of mannitol to identify EIB was 59%/65% and for methacholine it was 56%/69%. The BHR was mild. Mean EIB % fall in FEV1 in subjects positive to exercise was 19%, (SD 9.2), mannitol PD15 158 (CI:129,193) mg, and methacholine PC20 2.1(CI:1.7, 2.6) mg/ml. The prevalence of BHR was the same: for exercise (43.5%), mannitol (44.8%), and methacholine (41.6%) with a test agreement between 62 & 69%. The sensitivity and specificity for a clinician diagnosis of asthma was 56%/73% for mannitol and 51%/75% for methacholine. The sensitivity increased to 73% and 72% for mannitol and methacholine when two exercise tests were positive., Conclusion: In this group with normal FEV1, mild symptoms, and mild BHR, the sensitivity and specificity for both mannitol and methacholine to identify EIB and a clinician diagnosis of asthma were equivalent, but lower than previously documented in well-defined populations., Trial Registration: This was a multi-center trial comprising 25 sites across the United States of America.
- Published
- 2009
- Full Text
- View/download PDF
17. Exercise-induced hypersensitivity syndromes in recreational and competitive athletes: a PRACTALL consensus report (what the general practitioner should know about sports and allergy).
- Author
-
Schwartz LB, Delgado L, Craig T, Bonini S, Carlsen KH, Casale TB, Del Giacco S, Drobnic F, van Wijk RG, Ferrer M, Haahtela T, Henderson WR, Israel E, Lötvall J, Moreira A, Papadopoulos NG, Randolph CC, Romano A, and Weiler JM
- Subjects
- Anaphylaxis etiology, Asthma, Exercise-Induced etiology, Humans, Hypersensitivity diagnosis, Hypersensitivity therapy, Rhinitis etiology, Syndrome, Urticaria etiology, Exercise, Hypersensitivity etiology
- Abstract
Exercise-induced (EI) hypersensitivity disorders are significant problems for both recreational and competitive athletes. These include EI-asthma, EI-bronchoconstriction, EI-rhinitis, EI-anaphylaxis and EI-urticaria. A group of experts from the European Academy of Allergology and Clinical Immunology and the American Academy of Allergy Asthma and Immunology met to discuss the pathogenesis of these disorders and how to diagnose and treat them, and then to develop a consensus report. Key words (exercise with asthma, bronchoconstriction, rhinitis, urticaria or anaphylaxis) were used to search Medline, the Cochrane database and related websites through February 2008 to obtain pertinent information which, along with personal reference databases and institutional experience with these disorders, were used to develop this report. The goal is to provide physicians with guidance in the diagnosis, understanding and management of EI-hypersensitivity disorders to enable their patients to safely return to exercise-related activities.
- Published
- 2008
- Full Text
- View/download PDF
18. American Academy of Allergy, Asthma & Immunology Work Group report: exercise-induced asthma.
- Author
-
Weiler JM, Bonini S, Coifman R, Craig T, Delgado L, Capão-Filipe M, Passali D, Randolph C, and Storms W
- Subjects
- Asthma, Exercise-Induced drug therapy, Asthma, Exercise-Induced epidemiology, Diagnosis, Differential, Humans, Prevalence, Societies, Medical, Sports, United States, Asthma, Exercise-Induced diagnosis, Asthma, Exercise-Induced therapy, Exercise
- Published
- 2007
- Full Text
- View/download PDF
19. Asthma and athletes: therapy to compete.
- Author
-
Weiler JM and Malloy C
- Subjects
- Asthma, Exercise-Induced drug therapy, Doping in Sports, Humans, Sports Medicine, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy, Sports
- Abstract
Asthma presents special challenges to both the athletes who have it and to their health care providers. This article briefly reviews the problem of asthma--especially exercise-induced asthma--in the competitive athlete, and then describes treatments that are effective in controlling asthma. Drug-doping regulations are explained, as is the worldwide impact of drug doping on competitive athletes who have asthma. This review concludes with recommendations for competitive athletes and their health care providers regarding how to deal with asthma in this patient population.
- Published
- 2005
- Full Text
- View/download PDF
20. Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent asthma.
- Author
-
Weiler JM, Nathan RA, Rupp NT, Kalberg CJ, Emmett A, and Dorinsky PM
- Subjects
- Administration, Inhalation, Adolescent, Adult, Albuterol administration & dosage, Albuterol therapeutic use, Androstadienes therapeutic use, Child, Double-Blind Method, Drug Combinations, Exercise Test, Female, Fluticasone, Fluticasone-Salmeterol Drug Combination, Forced Expiratory Volume drug effects, Humans, Male, Middle Aged, Albuterol analogs & derivatives, Albuterol pharmacology, Androstadienes administration & dosage, Androstadienes pharmacology, Anti-Asthmatic Agents administration & dosage, Asthma, Exercise-Induced drug therapy
- Abstract
Background: Exercise is a common trigger of asthma symptoms in patients with persistent asthma., Objective: To evaluate the protective effect of fluticasone/salmeterol against exercise-induced bronchospasm., Methods: Multicenter, randomized, double-blind, parallel-group trial of 192 asthma patients who used moderate-dose inhaled corticosteroids. Patients (aged 12-50 years; mean forced expiratory volume in 1 second [FEV1], 78% of predicted at baseline) were randomized to receive fluticasone/salmeterol (250/50 microg twice daily) or fluticasone alone (250 microg twice daily) via Diskus for 4 weeks. Exercise challenge tests were performed 1 and 8.5 hours after administration of the first (day 1) and last (week 4) doses of blinded study medication., Results: On day 1 and at week 4, mean +/- SEM values for the maximal percentage decline in FEV1 1 hour after drug administration were 11.4% +/- 1.5% and 10.9% +/- 1.5% for fluticasone/salmeterol compared with 20.0% +/- 1.7% and 18.4% +/- 1.8% for fluticasone (P < .001). At 8.5 hours, mean +/- SEM values on day 1 and at week 4 were 11.6% +/- 1.4% and 8.9% +/1.1%, respectively, for fluticasone/salmeterol and 12.6% +/- 1.6% and 12.9% +/- 1.4%, respectively, for fluticasone (P = .01 at week 4). More fluticasone-treated patients did not complete the 8.5-hour exercise challenges (36% on day 1 and 33% at week 4) compared with the fluticasone/salmeterol group (18% each) (P < or = .01). Improvements in peak expiratory flow rate and albuterol rescue-free days were significantly greater with fluticasone/salmeterol vs fluticasone over weeks 1 to 4 (P < or = .03)., Conclusions: Consistent with the improvements in other measures of asthma control, long-term fluticasone/salmeterol therapy also provided protection against exercise-induced bronchospasm in patients with persistent asthma.
- Published
- 2005
- Full Text
- View/download PDF
21. Metabolic alteration of the N-glycan structure of a protein from patients with a heterozygous protein deficiency.
- Author
-
Zhang F, Bries AD, Lang SC, Wang Q, Murhammer DW, Weiler JM, and Linhardt RJ
- Subjects
- Angioedema metabolism, Carbohydrate Conformation, Carbohydrate Sequence, Complement C1 Inactivator Proteins, Complement C1 Inhibitor Protein, Electrophoresis, Capillary, Electrophoresis, Polyacrylamide Gel, Glycosylation, Heterozygote, Humans, Molecular Sequence Data, N-Acetylneuraminic Acid chemistry, N-Acetylneuraminic Acid metabolism, Neuraminidase metabolism, Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase metabolism, Polysaccharides genetics, Reference Values, Serpins chemistry, Serpins deficiency, Serpins genetics, Angioedema genetics, Polysaccharides chemistry, Polysaccharides metabolism, Protein Deficiency genetics, Serpins metabolism
- Abstract
Glycosylation, an important post-translation modification, could alter biological activity or influence the clearance rates of glycoproteins. We report here the first example of a heterozygous protein deficiency leading to metabolic alteration of N-glycan structures in residual secreted protein. Analysis of C1 esterase inhibitor (C1INH) glycans from normal individuals and patients with hereditary deficiency of C1INH demonstrated identical O-glycan structures but the N-glycans of patients with a heterozygous genetic deficiency were small, highly charged and lacked sialidase releasable N-acetylneuraminic acid. Structural studies indicate that the charge character of these aberrant N-glycan structures may result from the presence of mannose-6-phosphate residues. These residues might facilitate secretion of C1INH through an alternate lysosomal pathway, possibly serving as a compensatory mechanism to enhance plasma levels of C1INH in these deficient patients.
- Published
- 2004
- Full Text
- View/download PDF
22. Effect of short-term phytoestrogen treatment in male rats on nitric oxide-mediated responses of carotid and cerebral arteries: comparison with 17beta-estradiol.
- Author
-
Sobey CG, Weiler JM, Boujaoude M, and Woodman OL
- Subjects
- Animals, Carotid Arteries physiology, Cerebral Arteries physiology, Gene Expression drug effects, Male, Nitric Oxide Synthase metabolism, Phytoestrogens, Rats, Rats, Sprague-Dawley, Carotid Arteries drug effects, Cerebral Arteries drug effects, Estradiol pharmacology, Isoflavones pharmacology, Nitric Oxide physiology, Plant Preparations pharmacology
- Abstract
The use of estrogen for protection against vascular dysfunction is limited due to its effects on the reproductive system, particularly in males. We postulated that daidzein, an isoflavone with estrogen-like effects on the systemic vasculature but not the reproductive system, might enhance nitric oxide (NO)-mediated cerebral vasodilatation. Male rats were administered vehicle, 17beta-estradiol (0.1 mg/kg s.c.), or daidzein (0.2 mg/kg s.c.) daily for 7 days. Basal and acetylcholine-stimulated NO release was assessed in vitro via carotid arterial rings or in vivo by measuring changes in basilar artery diameter. Levels of protein expression of endothelial NO synthase (eNOS), caveolin-1, and calmodulin were assessed in carotid arteries using Western analysis. Plasma NO levels were doubled by daidzein or 17beta-estradiol. NO production and endothelium-dependent contraction in response to the NOS inhibitor NG-nitro-L-arginine (L-NNA; 100 microM) was enhanced by 50 to 100% in carotid arteries from rats treated with daidzein or 17beta-estradiol. Acetylcholine-induced relaxation was selectively enhanced in carotid arteries from rats treated with daidzein. Similarly, constrictor responses of the basilar artery to L-NNA in vivo were selectively augmented by approximately 100% by 17beta-estradiol treatment and tended to be approximately 50% greater in daidzein-treated rats. Expression of caveolin-1 was decreased, and calmodulin was increased, in vessels from daidzein- or 17beta-estradiol-treated rats. eNOS expression was unaffected by the treatments. These data suggest that short-term administration of daidzein or 17beta-estradiol modulates cerebral artery reactivity in males by enhancing synthesis and release of endothelium-derived NO. Isoflavone therapy may therefore be a feasible approach to protect against cerebrovascular disease and stroke.
- Published
- 2004
- Full Text
- View/download PDF
23. Quality of patient-reported outcome data captured using paper and interactive voice response diaries in an allergic rhinitis study: is electronic data capture really better?
- Author
-
Weiler K, Christ AM, Woodworth GG, Weiler RL, and Weiler JM
- Subjects
- Adult, Cross-Over Studies, Data Collection instrumentation, Electronic Data Processing, Electronics, Female, Humans, Male, Reproducibility of Results, Rhinitis, Allergic, Seasonal physiopathology, Sensitivity and Specificity, Data Collection methods, Outcome Assessment, Health Care
- Abstract
Background: Accuracy and reliability of diary data collected in allergic rhinitis trials depends on how and when the information is recorded by the subjects., Objective: To compare diary data collected by using paper (optical mark readable) and electronic [telephone, interactive voice response system (IVRS)] tools., Methods: There was a randomized, 3-week, 3-way, crossover trial, in 87 adults with allergic rhinitis recording diary data at home. Outcome measures were (1) comparison of symptom data during weeks when both or only 1 instrument was used; (2) missing data: and (3) ease of use and participant preference., Results: More than 40,000 symptom data elements were recorded by 72 protocol-correct subjects. Symptoms recorded during the week that both instruments were used and when the 2 instruments were used alone were indistinguishable. Overall, 0.45% of paper and 4.12% of IVRS symptom data were missing. Of 10,080 paired data collected on paper and IVRS diaries during the week in which subjects used both, 94.44% were identical. Using IVRS, 63.2% of protocol-correct data were entered within the designated time and 87.6% within 1 half-day of the time specified; 85% of subjects preferred the paper instrument, 4% preferred IVRS, and 11% had no preference., Conclusions: A paper-based instrument can capture data indistinguishable from data captured from an electronic product. Processes to collect diary data should be evaluated for each study rather than simply to use the "latest" technology. Another interpretation is that frequency of recording diary data does not have a significant impact on outcomes.
- Published
- 2004
- Full Text
- View/download PDF
24. Efficacy and safety of clemastine-pseudoephedrine-acetaminophen versus pseudoephedrine-acetaminophen in the treatment of seasonal allergic rhinitis in a 1-day, placebo-controlled park study.
- Author
-
Meltzer EO, Casale TB, Gold MS, O'Connor R, Reitberg D, del Rio E, Weiler JM, and Weiler K
- Subjects
- Adolescent, Adult, California epidemiology, Child, Dose-Response Relationship, Drug, Double-Blind Method, Drug Evaluation, Drug Therapy, Combination, Female, Headache complications, Headache drug therapy, Headache epidemiology, Humans, Incidence, Male, Middle Aged, Nasal Decongestants therapeutic use, Nebraska epidemiology, Rhinitis, Allergic, Seasonal complications, Rhinitis, Allergic, Seasonal epidemiology, Severity of Illness Index, Time Factors, Treatment Outcome, Acetaminophen therapeutic use, Analgesics, Non-Narcotic therapeutic use, Bronchodilator Agents therapeutic use, Clemastine therapeutic use, Ephedrine therapeutic use, Histamine H1 Antagonists therapeutic use, Rhinitis, Allergic, Seasonal drug therapy
- Abstract
Background: Allergic rhinitis afflicts more than 40 million people in the United States and is a leading cause of reduced productivity at work and in school. Patients with allergic rhinitis have a wide range of symptoms that are often treated with oral combination products that contain antihistamines, decongestants, and analgesics., Objective: To evaluate the onset of action and the extent of efficacy and safety of a combination (CPA) of clemastine (0.68 mg), pseudoephedrine (60 mg), and acetaminophen (1,000 mg) versus a combination (PA) of pseudoephedrine and acetaminophen versus placebo in the treatment of seasonal allergic rhinitis (SAR). The primary goal was to evaluate the benefit of adding clemastine to the PA combination product to treat the symptoms of SAR., Method: A 1-day, multicenter, double-blind, double-dummy, randomized, parallel-group park study was organized, and medication was given at 9:00 AM and 3:00 PM., Results: A total of 298 subjects participated at two outdoor facilities. The primary efficacy outcome was the major symptom complex score averaged over the period of 2 to 5 hours after each dose. Mean absolute and percentage reduction in major symptom complex averaged over the period of 2 to 5 hours in the CPA group was significantly superior to those of either the PA (P < 0.01) or placebo (P < 0.03) groups. Somnolence, fatigue, and nausea were the most common volunteered adverse events; only somnolence was significantly greater after CPA than after either PA or placebo., Conclusions: Treatment with CPA was safe and highly effective in reducing symptoms associated with SAR. It was more effective than either PA or placebo over most of the postdose observation period.
- Published
- 2003
- Full Text
- View/download PDF
25. Why must olympic athletes prove that they have asthma to be permitted to take inhaled beta2-agonists?
- Author
-
Weiler JM
- Subjects
- Administration, Inhalation, Adrenergic beta-Agonists administration & dosage, Adrenergic beta-Agonists therapeutic use, Asthma diagnosis, Asthma drug therapy, Sports
- Published
- 2003
- Full Text
- View/download PDF
26. The real-world risk of taking sedating antihistamines.
- Author
-
Weiler JM
- Subjects
- Accidents, Drug Labeling, Humans, Risk, Anti-Allergic Agents adverse effects, Histamine H1 Antagonists adverse effects, Hypnotics and Sedatives adverse effects
- Published
- 2002
- Full Text
- View/download PDF
27. Does heparin prophylaxis prevent exacerbations of hereditary angioedema?
- Author
-
Weiler JM, Quinn SA, Woodworth GG, Brown DD, Layton TA, and Maves KK
- Subjects
- Acute Disease, Administration, Inhalation, Adolescent, Adult, Aged, Angioedema genetics, Child, Complement C1 Inactivator Proteins genetics, Cross-Over Studies, Double-Blind Method, Female, Heparin administration & dosage, Humans, Injections, Subcutaneous, Male, Middle Aged, Patient Compliance, Angioedema prevention & control, Heparin therapeutic use
- Abstract
Background: Hereditary angioedema (HAE) is a rare disorder characterized by episodes of angioedema of the skin, mucous membranes, and gastrointestinal tract resulting from a defect in the gene that produces C1 esterase inhibitor. Although in vitro laboratory data and past reports suggested that heparin might be efficacious in preventing HAE attacks, no controlled study has been reported to examine heparin's efficacy in this regard., Objectives: We sought to determine the safety and efficacy of inhaled and subcutaneous heparin versus that of placebo in the prevention of HAE attacks., Methods: We performed a double-blind, double-dummy, saline placebo-controlled, randomized, 3-way crossover study with 11 visits., Results: The study was designed to enroll 24 patients. Twenty-two patients were randomized and received the study drug. Patients did not have a significant decrease in average flare intensity after they received injected or inhaled heparin compared with that seen after placebo, the primary endpoint. However, when patients received injected heparin, they had a statistically significant decrease in average flare intensity compared with that seen with inhaled heparin after a normalizing transformation was applied. When the means are back transformed, this translates into median flare intensities of 9.2, 8.0, and 5.1 in the patients treated with inhaled heparin, placebo, and injected heparin, respectively. There were no significant differences when individual symptoms were examined, when total numbers of flares over a 6-week observation period were examined, or when global evaluations by the patients and investigators were evaluated. Adverse event severity was fairly uniform across treatments, with the majority of events classified as moderate and the remainder split between mild and severe. Injected heparin treatment was associated with higher rates of relatedness than other treatments, which was partially explained by 17 adverse events specifically related to the injection process itself (tenderness, bruising, redness, pain, and itching at the injection site). The injection treatment was also associated with a larger overall number of reported adverse events (70 vs 48 in the placebo treatment). Tenderness and bruising at the injection site were entirely confined to the injected heparin treatment., Conclusions: Injected and inhaled heparin failed to attenuate average flare intensity, the primary endpoint, compared with placebo. Interestingly, after patients injected heparin, they had a significant decrease in average flare intensity compared with that seen after inhalation of heparin. There were no differences among groups in other efficacy parameters. Taken together, these data indicate that commercial heparin was ineffective in preventing exacerbations of HAE.
- Published
- 2002
- Full Text
- View/download PDF
28. Sedation, cognition, and antihistamines.
- Author
-
Qidwai JC, Watson GS, and Weiler JM
- Subjects
- Histamine H1 Antagonists therapeutic use, Humans, Neuropsychological Tests, Psychomotor Performance drug effects, Rhinitis, Allergic, Perennial drug therapy, Rhinitis, Allergic, Seasonal drug therapy, Cognition drug effects, Histamine H1 Antagonists adverse effects, Sleep Stages drug effects
- Abstract
First-generation antihistamines are well-known to cause subjective drowsiness. A myriad of studies has also been published that suggest a clear relationship between the use of these drugs and objective performance impairment. Although not all of the tests used in these studies have been validated, the data are fairly consistent, and suggest a difference between earlier (first-generation) sedating antihistamines and the newer (second-generation) nonsedating antihistamines.
- Published
- 2002
- Full Text
- View/download PDF
29. A report of a rare immediate reaction after ingestion of acetaminophen.
- Author
-
Grant JA and Weiler JM
- Subjects
- Adolescent, Female, Humans, Acetaminophen adverse effects, Analgesics, Non-Narcotic adverse effects, Drug Hypersensitivity, Hypersensitivity, Immediate chemically induced
- Abstract
Background: Acetaminophen hypersensitivity is rare and, when seen, is usually in association with sensitivity to nonsteroidal anti-inflammatory drugs., Methods: This is a case report of an immediate reaction to acetaminophen, confirmed by a drug challenge, in a subject who tolerated ibuprofen., Results: After an oral challenge with 50 mg of acetaminophen, the subject had generalized pruritus, urticaria, and dyspnea., Conclusions: This patient demonstrates a rare but potentially severe reaction to acetaminophen that may occur in patients who are not otherwise sensitive to other nonsteroidal anti-inflammatory drugs.
- Published
- 2001
- Full Text
- View/download PDF
30. Expression of C1 esterase inhibitor by the baculovirus expression vector system: preparation, purification, and characterization.
- Author
-
Wolff MW, Zhang F, Roberg JJ, Caldwell EE, Kaul PR, Serrahn JN, Murhammer DW, Linhardt RJ, and Weiler JM
- Subjects
- Animals, Baculoviridae genetics, Complement C1 Inactivator Proteins isolation & purification, Complement C1 Inactivator Proteins metabolism, Genetic Vectors, Humans, Polysaccharides chemistry, Recombinant Proteins biosynthesis, Recombinant Proteins isolation & purification, Spodoptera, Complement C1 Inactivator Proteins genetics
- Abstract
C1 esterase inhibitor (C1INH) is an important regulator of the classical complement pathway. Hereditary deficiency of C1INH causes angioedema of the skin, gut, and respiratory tissues that may be fatal. C1INH replacement therapy may be lifesaving for patients with this disorder. The objective of this study was to evaluate the use of the baculovirus expression vector system for mass producing biologically active human recombinant (rC1INH). A recombinant baculovirus was constructed coding the human native (nC1INH) sequence under control of the polyhedrin promoter. Spodoptera frugiperda Sf-9 insect cells were infected with this recombinant baculovirus in a medium-scale (10-L) bioreactor to produce rC1INH with a specific activity of 45 U/mg. Purification of rC1INH from the culture harvested at 60 h postinfection yielded 5.9 microg rC1INH/mL supernatant of a 75-kDa product with a specific activity of 31,000 U/mg purified rC1INH compared to 71,000 U/mg purified nC1INH from human serum using the same procedure. This rC1INH was about 25 kDa smaller than nC1INH, suggesting that Sf-9 cells express underglycosylated rC1INH. Glycan analysis showed that both N-glycan and O-glycan chains were present in rC1INH. The N-glycan chains, released using PNGaseF and fluorescently labeled, were analyzed using exoglycosidase treatment and capillary electrophoresis. Their high-mannose structure was consistent with the known failure of the insect cell glycosylation pathway to afford the fully elaborated biantennary structures found on human native nC1INH., (Copyright 2001 Academic Press.)
- Published
- 2001
- Full Text
- View/download PDF
31. Certain high molecular weight heparin chains have high affinity for vitronectin.
- Author
-
Edens RE, LeBrun LA, Linhardt RJ, Kaul PR, and Weiler JM
- Subjects
- Electrophoresis, Gel, Two-Dimensional, Humans, Molecular Weight, Polymers metabolism, Heparin metabolism, Vitronectin metabolism
- Abstract
Vitronectin is a 70-kDa protein that is found in both the extracellular matrix as well as serum. Vitronectin is one of the few proteins that regulates both the complement and the coagulation systems. Heparin is known to bind to vitronectin. Review of the literature reveals apparently conflicting outcomes of the interaction of heparin, vitronectin, and the complement system. Previous studies demonstrated that heparin diminishes vitronectin inhibition of complement activity. Numerous studies have also demonstrated that heparin exerts a net inhibitory effect on complement. We used two dimensional affinity resolution electrophoresis (2DARE) to examine this apparent paradox. 2DARE allowed simultaneous determination of binding affinity of heparin for vitronectin as well as the M(r) of the heparin species. In the 2DARE experiment, the interaction of heparin with vitronectin caused retardation of the movement of the heparin through the tube gel in the first dimension. The degree of the retardation of movement was used to calculate the approximate K(d) of that interaction. The heparin from the tube gel was then subjected to a second dimension electrophoresis to determine the M(r) of the heparin. 2DARE analysis of the interaction of heparin with vitronectin clearly demonstrated that a sub-population of heparin chains with M(r) > 8000 bound vitronectin with high affinity whereas most high M(r) chains and all lower M(r) chains showed little to no affinity for vitronectin. Our findings are consistent with the hypothesis that a unique binding domain exists in certain heparin chains for vitronectin., (Copyright 2001 Academic Press.)
- Published
- 2001
- Full Text
- View/download PDF
32. A review of the reported defects in the human C1 esterase inhibitor gene producing hereditary angioedema including four new mutations.
- Author
-
Bowen B, Hawk JJ, Sibunka S, Hovick S, and Weiler JM
- Subjects
- Amino Acid Substitution, Angioedema classification, Complement C1 Inactivator Proteins genetics, DNA Mutational Analysis, Exons genetics, Humans, Introns genetics, Mutagenesis, Insertional, Mutation, Missense, Point Mutation, RNA Splicing genetics, Angioedema genetics, Complement C1 Inactivator Proteins deficiency, Mutation
- Abstract
C1 esterase inhibitor (C1INH) is an important regulatory protein of the classical pathway of complement. Mutations in the gene for this protein cause the autosomal dominant disorder hereditary angioedema (HAE). Approximately 85% of patients with HAE have a Type I defect, characterized by a diminished level of antigenic and functional C1INH. Patients with Type II defects have sufficient protein, but one allele produces dysfunctional protein. We have sequenced the DNA from HAE patients and have discovered four previously unreported mutations. The first mutation is a splice site error at nucleotide 8721, which changes the 3' acceptor splice site AG to GG at the end of intron 5 at nucleotide 8721-8722. The second mutation is a single base insertion in exon 3 between nucleotides 2467 and 2468. The third mutation is a missense error present in the eighth exon of the C1INH; at nucleotide 16867 (amino acid 470), a T to A mutation transforms a Met to a Lys. The fourth mutation closely resembles the third mutation in that it is a missense error occurring in exon 8 in the distal hinge region; a T16827C substitution changes the Phe at amino acid 457 to Leu. This report compiles a list of 97 distinct defects in the C1INH gene that cause hereditary angioedema., (Copyright 2000 Academic Press.)
- Published
- 2001
- Full Text
- View/download PDF
33. Asthma in United States olympic athletes who participated in the 1998 olympic winter games.
- Author
-
Weiler JM and Ryan EJ 3rd
- Subjects
- Asthma drug therapy, Female, Humans, Male, Seasons, Surveys and Questionnaires, United States epidemiology, Asthma epidemiology, Sports
- Abstract
Background: About one of every 5 athletes who participated in the 1996 Summer Olympic Games in Atlanta had a past history of asthma, had symptoms that suggested asthma, or took asthma medications. No previous study has determined the prevalence of asthma in all US athletes who participated in an Olympic Winter Games., Objectives: We sought to determine how many US athletes who participated in the 1998 Olympic Winter Games had a past history of asthma, had symptoms that suggested asthma, or indicated taking a medication used to treat asthma., Methods: We evaluated responses to questions that asked about allergic and respiratory diseases in the United States Olympic Committee Medical History Questionnaire that was completed by all 196 athletes who represented the United States at the 1998 Olympic Winter Games in Nagano, Japan., Results: Forty-three (21.9%) of the 196 athletes had a previous diagnosis of asthma, and 36 (18. 4%) recorded use of an asthma medication at some time in the past. Forty-four (22.4%) reported use of an asthma medication, a diagnosis of asthma, or both (our basis for the diagnosis of asthma). Thirty-four (17.4%) of the athletes were currently taking an asthma medication at the time that they completed the questionnaire or indicated that they took these medications on a permanent or semipermanent basis and were considered to have active asthma. Athletes who participated in Nordic combined, cross-country, and short track events had the highest prevalence of having been told that they had asthma or had taken an asthma medication in the past (60.7%) in contrast with only one (2.8%) of the 36 athletes who participated in bobsled, biathlon, luge, and ski jumping. Eighteen (24%) of 75 athletes who participated in alpine, long track, figure skating, snow boarding, and curling had a previous diagnosis of asthma or recorded use of an asthma medication., Conclusions: We conclude that asthma appeared to have been more common in athletes who participated in the 1998 Winter Games than in athletes who participated in either the 1996 or 1984 Summer Games. Clearly, asthma rates vary widely among sports. This suggests that the environment in which exercise is performed is important in leading to a decrease in the amount of exercise required to trigger asthma and perhaps in causing injury to the airways.
- Published
- 2000
- Full Text
- View/download PDF
34. Effect of IGFBP-derived peptides on incorporation of(35)SO(4)into proteoglycans.
- Author
-
Booth BA, Boes M, Dake BL, Caldwell EE, Weiler JM, and Bar RS
- Subjects
- Amino Acid Sequence, Animals, Cattle, Cells, Cultured, Endothelium, Vascular cytology, Endothelium, Vascular drug effects, Endothelium, Vascular metabolism, Insulin-Like Growth Factor Binding Protein 3 chemistry, Insulin-Like Growth Factor Binding Protein 3 genetics, Insulin-Like Growth Factor Binding Protein 3 pharmacology, Insulin-Like Growth Factor Binding Protein 5 chemistry, Insulin-Like Growth Factor Binding Protein 5 genetics, Insulin-Like Growth Factor Binding Protein 5 pharmacology, Insulin-Like Growth Factor Binding Protein 6 chemistry, Insulin-Like Growth Factor Binding Protein 6 genetics, Insulin-Like Growth Factor Binding Protein 6 pharmacology, Insulin-Like Growth Factor Binding Proteins chemistry, Insulin-Like Growth Factor Binding Proteins genetics, Molecular Sequence Data, Peptide Fragments chemistry, Peptide Fragments genetics, Peptide Fragments pharmacology, Insulin-Like Growth Factor Binding Proteins pharmacology, Proteoglycans metabolism, Sulfates metabolism
- Abstract
18 amino acid peptides from the C-terminal region of IGFBP-3, -5 (P3, P5), increased the incorporation of(35)SO(4)into proteoglycans in endothelial cells with greater stimulation in large vessel than microvessel cells. The homologous region of IGFBP-6 (P6) also stimulated sulfate uptake, but less potently than P3 and P5. P6 variants were synthesized with one or two amino acids changed to the basic amino acid in the equivalent position of P3. The P6 variants with one additional basic amino acid behaved similarly to P6. The P6 mutant with two altered amino acids was equipotent to P3. P3F, a scrambled version of P3 was less effective than P3. P3, P5, P6, P3F and all P6 variants all stimulated glucose uptake, which occurred only in microvessel cells. P1, P2, P4, and equimolar intact IGFBP-3 stimulated neither glucose uptake nor sulfate incorporation. Thus, C-terminal basic portions of IGFBP-3, -5 and -6 alter two specific functions of endothelial cells with sufficient differences to suggest mediation by distinct mechanisms., (Copyright 2000 Harcourt Publishers Ltd.)
- Published
- 2000
- Full Text
- View/download PDF
35. Anaphylaxis in the general population: A frequent and occasionally fatal disorder that is underrecognized.
- Author
-
Weiler JM
- Subjects
- Anaphylaxis diagnosis, Humans, Minnesota epidemiology, Anaphylaxis epidemiology
- Published
- 1999
- Full Text
- View/download PDF
36. Heparin binding and augmentation of C1 inhibitor activity.
- Author
-
Caldwell EE, Andreasen AM, Blietz MA, Serrahn JN, VanderNoot V, Park Y, Yu G, Linhardt RJ, and Weiler JM
- Subjects
- Adjuvants, Pharmaceutic pharmacology, Animals, Binding Sites drug effects, Cattle, Complement C1 metabolism, Dose-Response Relationship, Drug, Enzyme Activation drug effects, Extracellular Space chemistry, Extracellular Space enzymology, Glycosaminoglycans metabolism, Kidney cytology, Time Factors, Adjuvants, Pharmaceutic metabolism, Complement C1 Inactivator Proteins metabolism, Complement C1 Inactivator Proteins pharmacology, Heparin metabolism, Heparin pharmacology
- Abstract
Heparin and other glycosaminoglycans have profound activity in vitro on the regulation of complement activity. The studies reported here examined the mechanism whereby heparin enhances C1 esterase inhibitor (C1INH) activity on C1 esterase (C1). The interaction of heparin and heparan sulfate with C1INH was first examined using surface plasmon resonance. Heparin was immobilized on a biosensor chip in two orientations, at its reducing end and in midchain, and heparan sulfate was immobilized at its reducing end. Heparin immobilized at its reducing end interacted with C1INH, giving an association constant (Ka) value of 1.43 x 10(7) M-1, whereas heparin immobilized in midchain afforded a Ka value of 7 x 10(6) M-1. No interaction between C1INH and heparan sulfate could be observed. Next, the augmentation of C1INH by heparin (Mr (av) 13,000), low-molecular-weight (LMW) heparin (Mr (av) 5000), and heparan sulfate (Mr (av) 11,000) was determined. C1INH alone was at least 10, 000 times more active in inhibiting fluid phase C1 compared with erythrocyte-bound C1 (EAC1). When C1 was in the fluid phase, both heparin and LMW heparin were relatively ineffective at augmenting C1INH activity on C1. In contrast, when C1 was present as EAC1, heparin augmented C1INH activity at all C1INH concentrations examined and LMW heparin was up to 1.3 times more effective than heparin. This augmentation only occurred when both C1INH and heparin were present together with the EAC1. Hence, although surface plasmon resonance shows that heparin binds to C1INH, heparin augmentation of C1INH activity appears to require a terniary complex in which cell bound C1 interacts with both heparin and C1INH. This is the first report of LMW heparin augmenting C1INH activity. Heparan sulfate neither interacted with C1INH nor did it augment C1INH activity., (Copyright 1999 Academic Press.)
- Published
- 1999
- Full Text
- View/download PDF
37. Asthma in United States Olympic athletes who participated in the 1996 Summer Games.
- Author
-
Weiler JM, Layton T, and Hunt M
- Subjects
- Asthma, Exercise-Induced epidemiology, Drug Hypersensitivity epidemiology, Female, Humans, Male, Medical History Taking, Prevalence, Respiratory Hypersensitivity epidemiology, Seasons, Surveys and Questionnaires, United States epidemiology, Asthma epidemiology, Sports physiology
- Abstract
Background: Asthma prevalence appears to be increasing in the general population. We sought to determine whether asthma prevalence has also increased in highly competitive athletes., Objective: Our aim was to determine how many United States Olympic athletes who were chosen to participate in the 1996 Summer Olympic Games had a past history of asthma or symptoms that suggested asthma or took asthma medications., Methods: We analyzed responses to questions that asked about allergic and respiratory diseases on the United States Olympic Committee (USOC) Medical History Questionnaire that was completed by all athletes who were chosen to represent the US at the 1996 Summer Olympic Games in Atlanta., Results: Of the 699 athletes who completed the questionnaire, 107 (15.3%) had a previous diagnosis of asthma, and 97 (13.9%) recorded use of an asthma medication at some time in the past. One hundred seventeen (16.7%) reported use of an asthma medication, a diagnosis of asthma, or both (which was our basis for the diagnosis of asthma). Seventy-three (10. 4%) of the athletes were currently taking an asthma medication at the time that they were processed in Atlanta or noted that they took asthma medications on a permanent or semipermanent basis and were considered to have active asthma. Athletes who participated in cycling and mountain biking had the highest prevalence of having been told that they had asthma or had taken an asthma medication in the past (50%). Frequency of active asthma varied from 45% of cyclists and emountain bikers to none of the divers and weight lifters. Only about 11% of the athletes who participated in the 1984 Summer Olympic Games were reported to have had exercise-induced asthma on the basis of other criteria that may have been less restrictive. On the basis of these less restrictive criteria, more than 20% of the athletes who participated in the 1996 Olympic Games might have been considered to have had asthma., Conclusions: Asthma appeared to have been more prevalent in athletes who participated in the 1996 Summer Games than in the general population or in those who participated in the 1984 Summer Games. This study also suggests that asthma may influence the sport that an athlete chooses.
- Published
- 1998
- Full Text
- View/download PDF
38. C1 esterase inhibitor deficiency, airway compromise, and anesthesia.
- Author
-
Jensen NF and Weiler JM
- Subjects
- Humans, Airway Obstruction etiology, Airway Obstruction therapy, Anesthesia, Angioedema complications, Angioedema diagnosis, Angioedema genetics, Angioedema therapy, Complement C1 Inactivator Proteins deficiency
- Published
- 1998
- Full Text
- View/download PDF
39. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins.
- Author
-
Hileman RE, Fromm JR, Weiler JM, and Linhardt RJ
- Subjects
- Amino Acid Sequence, Amino Acids metabolism, Binding Sites, Carbohydrate Sequence, Consensus Sequence genetics, Models, Molecular, Molecular Sequence Data, Protein Binding, Protein Structure, Secondary, Thermodynamics, Glycosaminoglycans chemistry, Proteins metabolism
- Abstract
Although interactions of proteins with glycosaminoglycans (GAGs), such as heparin and heparan sulphate, are of great biological importance, structural requirements for protein-GAG binding have not been well-characterised. Ionic interactions are important in promoting protein-GAG binding. Polyelectrolyte theory suggests that much of the free energy of binding comes from entropically favourable release of cations from GAG chains. Despite their identical charges, arginine residues bind more tightly to GAGs than lysine residues. The spacing of these residues may determine protein-GAG affinity and specificity. Consensus sequences such as XBBBXXBX, XBBXBX and a critical 20 A spacing of basic residues are found in some protein sites that bind GAG. A new consensus sequence TXXBXXTBXXXTBB is described, where turns bring basic interacting amino acid residues into proximity. Clearly, protein-GAG interactions play a prominent role in cell-cell interaction and cell growth. Pathogens including virus particles might target GAG-binding sites in envelope proteins leading to infection.
- Published
- 1998
- Full Text
- View/download PDF
40. Interaction of fibroblast growth factor-1 and related peptides with heparan sulfate and its oligosaccharides.
- Author
-
Fromm JR, Hileman RE, Weiler JM, and Linhardt RJ
- Subjects
- Amino Acid Sequence, Animals, Binding Sites, Calorimetry, Chromatography, Affinity, Electrophoresis, Polyacrylamide Gel, Intestinal Mucosa metabolism, Models, Molecular, Molecular Conformation, Molecular Sequence Data, Peptide Fragments chemical synthesis, Peptide Fragments metabolism, Protein Binding, Protein Structure, Secondary, Swine, Thermodynamics, Fibroblast Growth Factors metabolism, Heparitin Sulfate metabolism, Oligosaccharides metabolism
- Abstract
Fibroblast growth factors (FGFs) are a family of angiogenic and mitogenic proteins that promote cell division. The binding of FGFs to the heparan sulfate of cell-surface-bound proteoglycans appears to be critical for their activity. The interaction of fibroblast growth factor-1 (FGF-1 or aFGF) using heparin lyase-derived oligosaccharides from heparan sulfate was investigated. FGF-1 was also shown to protect sequences in heparan sulfate from heparin lyase digestion and protected oligosaccharide products of octasaccharide and decasaccharide size were recovered by FGF-1 affinity chromatography, suggesting that the high-affinity binding of heparan sulfate to FGF-1 resides within an octasaccharide sequence. The FGF-1 binding affinity of heparan sulfate is reduced compared to heparin presumably due to the absence of 6-sulfate groups in heparan sulfate. Inspection of the FGF-1 heparan sulfate binding domain shows that the majority of interacting amino acids are contained within a 20-amino-acid sequence that folds back upon itself (because of three turns) forming a triangular shaped cup of positive charge. The importance of FGF-1 binding site topology was investigated using three synthetic peptide mimics of the FGF-1 glycosaminoglycan (GAG) binding site. Heparan sulfate affinity chromatography and isothermal titration calorimetry, used to measure binding thermodynamics, demonstrated that a synthetic peptide analogous to the GAG binding site in FGF-1 bound tightly to heparan sulfate. A peptide containing a D-proline in place of L-proline bound with considerably reduced affinity, presumably due to the altered structure of the second turn in the binding site. A cyclic peptide, expected to be topologically most similar to the triangular GAG binding site in FGF-1, bound with the highest affinity to heparan sulfate. These data suggest the triangular topology of the GAG binding site in FGF is critical for its interaction with heparan sulfate. Analysis of known GAG binding sites in 25 proteins using the Chou-Fasman algorithm show that these sites commonly contain turns.
- Published
- 1997
- Full Text
- View/download PDF
41. Azelastine nasal spray as adjunctive therapy to azelastine tablets in the management of seasonal allergic rhinitis.
- Author
-
Weiler JM and Meltzer EO
- Subjects
- Administration, Inhalation, Administration, Intranasal, Administration, Oral, Adolescent, Adult, Aged, Child, Double-Blind Method, Female, Headache chemically induced, Humans, Male, Middle Aged, Phthalazines adverse effects, Phthalazines standards, Severity of Illness Index, Tablets, Taste Disorders chemically induced, Bronchodilator Agents administration & dosage, Phthalazines administration & dosage, Rhinitis, Allergic, Seasonal drug therapy
- Abstract
Background: Azelastine rhinitis medications (nasal spray and tablets) have been shown to relieve the symptoms of allergic rhinitis. Nevertheless, many rhinitic subjects suffer from acute exacerbations of symptoms that sometimes require additional treatment., Objective: To assess the efficacy and safety of azelastine nasal spray as adjunctive therapy to azelastine tablets in the management of symptomatic seasonal allergic rhinitis in subjects who remain symptomatic despite the oral medication., Methods: A 2-day, randomized, multicenter, double-blind, placebo-controlled, parallel-group study. Two hundred thirty-three subjects with symptomatic allergic rhinitis received azelastine tablets (0.5 mg bid) for a minimum of seven days prior to receiving either azelastine nasal spray (2 sprays per nostril bid) or placebo nasal spray as adjunctive therapy. Efficacy was determined by improvement in rhinitis symptoms that were grouped according to total and major symptom complex severity scores., Results: Mean percent improvements in the total symptom complex severity scores for azelastine were statistically significant (P < or = .05) or showed a trend toward statistical significance (.05 < or = P < .10) versus placebo from the second through the first ten hours after the initial dose and for each of the last five hours of the second day, demonstrating a rapid onset of action and sustained efficacy over the 2-day study period. Azelastine was well tolerated, and no subject discontinued therapy with azelastine due to an adverse experience., Conclusion: Azelastine nasal spray can be effectively administered as adjunctive therapy, in an outdoor environment in which subjects are exposed to pollen and other aeroallergens.
- Published
- 1997
- Full Text
- View/download PDF
42. What exactly is exercise-induced asthma?
- Author
-
Weiler JM
- Subjects
- Adolescent, Bronchial Spasm diagnosis, Humans, Asthma, Exercise-Induced diagnosis
- Published
- 1997
- Full Text
- View/download PDF
43. Pattern and spacing of basic amino acids in heparin binding sites.
- Author
-
Fromm JR, Hileman RE, Caldwell EE, Weiler JM, and Linhardt RJ
- Subjects
- Amino Acid Sequence, Binding Sites, Calorimetry, Chromatography, Affinity, Heparin metabolism, Molecular Sequence Data, Spectrometry, Mass, Fast Atom Bombardment, Amino Acids chemistry, Heparin chemistry
- Abstract
Glycosaminoglycan (GAG)-protein interactions regulate a myriad of physiologic and pathologic processes, yet an understanding of how these molecules interact is lacking. The role of the pattern and spacing of basic amino acids (arginine (R) and lysine (K)) in heparin binding sites was investigated using peptide analogs as well as by examining known heparin binding sites. Peptides having the general structure R(n)W (n = 3-9, where tyrosine (W) was added for peptide detection) were synthesized and their interaction with heparin was determined by isothermal titration calorimetry. Binding affinity increased with increasing number of R residues. A 9-mer of R (R9W) bound as tightly to heparin as acidic fibroblast growth factor under physiologic conditions. Despite their high affinity for heparin, long stretches of basic amino acids are uncommon in heparin binding proteins. Known heparin binding sites most commonly contain single isolated basic amino acids separated by one nonbasic amino acid. Peptides having the structure, H3CCONH-GRRG(m)RRG(5-m)-CONH2 (denoted as the RRG(m)RR peptide series) and H3CCONH-GRRRG(m)RG(5-m)-CONH2 (denoted as the RRRG(m)R peptide series), where m = 0-5, were synthesized to test the hypothesis that the spacing of basic amino acids in heparin binding sites is optimally arranged to interact with different GAGs. The peptides, in both the -RRG(m)RR- and -RRRG(m)R- peptide series, when m = 0, bound most tightly with heparin, as measured by affinity chromatography. In contrast, the -RRG(m)RR-peptide series interacted most tightly with heparan sulfate when m = 0 or 1, whereas the -RRRG(m)R- peptide series bound tightest when m = 3. These results are consistent with our understanding of heparin and heparan sulfate structure. A highly sulfated GAG, such as heparin, interacts most tightly with peptides (or peptide sequences within proteins) containing a complementary binding site of high positive charge density. Heparan sulfate, having fewer and more highly spaced negatively charged groups, interacts most tightly with a complementary site on a peptide (or peptide sequences with proteins) that has more widely spaced cationic residues.
- Published
- 1997
- Full Text
- View/download PDF
44. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays.
- Author
-
Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, and Olson J
- Subjects
- Aged, Cardiopulmonary Bypass, Factor Xa Inhibitors, Heparin administration & dosage, Heparin blood, Humans, Middle Aged, Sensitivity and Specificity, Thrombelastography, Vascular Surgical Procedures, Blood Coagulation Tests, Heparin analysis
- Abstract
Objective: Laboratory and point-of-care coagulation tests are frequently obtained to determine the presence of heparin after surgical procedures. The objective of this study was (1) to compare the sensitivity of the activated coagulation time (ACT), activated partial thromboplastin time (aPTT), protamine titration (Hepcon; HMS Medtronic, Hemotec, Englewood, CO), and thromboelastography (TEG) with heparin anticoagulation and (2) to determine how frequently residual heparin is present in the 24-hour period after heparin neutralization in cardiopulmonary bypass (CPB) patients., Design: A prospective study., Setting: A tertiary care university teaching center that performs more than 15,000 surgical procedures per year., Participants: Vascular surgical (n = 17) and CPB (n = 29)., Interventions: In vascular surgical patients, coagulation tests (ACT, protamine titration [Hepcon], and TEG) were obtained before and 90 minutes after heparin (50 to 60 U/kg IV) and compared with heparin concentration determined by factor Xa inhibition assay. In cardiac surgical patients, ACT and heparin concentrations were measured after anesthesia induction, during CPB, after protamine neutralization, and 3 as well as 6 hours after CPB. In addition to heparin concentrations and ACT measures, platelet counts, fibrinogen levels, and bleeding times were determined before and 3 and 24 hours after CPB., Measurements and Main Results: Ninety minutes after heparin, significant heparin concentrations were present in all vascular surgical patients, but ACT was elevated in only 4 of 17 patients. Protamine titration (Hepcon) correlated with the factor Xa inhibitory assay for heparin (r2 = 0.76). All 17 patients had an abnormal TEG (mean "R" time = 81 +/- 39 minutes) and a marked elevation of aPTT (135 +/- 35 sec [normal 22 to 33 seconds]) 90 minutes after heparin. In CPB patients, ACT did not correlate with heparin assays. After protamine neutralization of heparin in CPB patients, ACT returned to baseline despite the presence of heparin in 3 of 29 patients (0.22, 0.18, and 0.33 U/mL)., Conclusions: ACT was less sensitive to residual heparin anticoagulation than aPTT, TEG, and whole blood heparin assay. The whole blood heparin assay (Hepcon) provided sensitive and specific data about the presence of residual heparin. Despite the limitation of ACT in detecting heparin, the investigators found that residual heparin was not common in the period after uncomplicated CPB.
- Published
- 1997
- Full Text
- View/download PDF
45. Structure-function relationships in the heparin-binding C-terminal region of insulin-like growth factor binding protein-3.
- Author
-
Booth BA, Boes M, Dake BL, Linhardt RJ, Caldwell EE, Weiler JM, and Bar RS
- Subjects
- Amino Acid Sequence, Animals, Antimetabolites metabolism, Cattle, Cells, Cultured, Deoxyglucose metabolism, Endothelium, Vascular metabolism, Extracellular Matrix metabolism, Fibroblast Growth Factors metabolism, Humans, Molecular Sequence Data, Recombinant Proteins pharmacology, Sequence Homology, Nucleic Acid, Structure-Activity Relationship, Anticoagulants metabolism, Heparin metabolism, Insulin-Like Growth Factor Binding Protein 3 metabolism
- Abstract
IGFBP-3 contains a carboxyterminal basic region which, when present as an isolated 18 amino acid peptide (P3), binds heparin, associates with cultured endothelial cells and stimulates glucose uptake. The P3 molecule has now been modified relative to charge, amino acid sequence and size to determine structure-function relationships relative to four properties of P3: affinity for heparin; inhibition of IGFBP-3 binding; stimulation of glucose uptake; and displacement of bFGF from the extracellular matrix of endothelial cells. Results indicate: (1) the presence or absence of heparin binding was concordant with the presence/absence of the other three properties; (2) the number of basic amino acids was an important, if not limiting, factor for each property; (3) the order of potency of the basic amino acids was arginine = lysine > > histidine; (4) the unrelated, basic protein, protamine, mimics all properties of P3; and (5) the putative consensus heparin-binding sequence of P3 was not essential for any of the P3 activities.
- Published
- 1996
46. Exercise-induced asthma: a practical guide to definitions, diagnosis, prevalence, and treatment.
- Author
-
Weiler JM
- Subjects
- Adult, Age Distribution, Child, Preschool, Guidelines as Topic, Humans, Prevalence, Prognosis, Risk Factors, Surveys and Questionnaires, Asthma, Exercise-Induced diagnosis, Asthma, Exercise-Induced epidemiology, Asthma, Exercise-Induced therapy
- Abstract
Exercise-induced asthma is defined as an intermittent narrowing of the airways, demonstrated by a decrease in some measure of flow, that the patient experiences as wheezing, chest tightness, coughing, and difficulty breathing that is triggered by exercise. Exercise will trigger asthma in most individuals who have chronic asthma, as well as in some who do not otherwise have asthma. Definitive diagnosis requires demonstration of a drop in flow rate, typically > or = 13-15% for forced expiratory volume in one second (FEV1) and > or = 15-20% for peak expiratory flow rate (PEFR), after exercise, associated with symptoms. Prevalence data indicate that this disorder is very common in those who participate in recreational sports as well as in highly competitive athletes, with at least 12-15% of unselected athletes having positive exercise challenges. Treatment of exercise induced asthma involves use of nonpharmacological measures (such as the use of the refractory period after exercise and prewarming air) as well as use of medications (beta-agonists, cromolyn, and nedocromil). With treatment, those who suffer from exercise-induced asthma may be able to participate and compete at the highest levels of performance.
- Published
- 1996
- Full Text
- View/download PDF
47. Preparation and biological activity of N-sulfonated chondroitin and dermatan sulfate derivatives.
- Author
-
Nadkarni VD, Toida T, Van Gorp CL, Schubert RL, Weiler JM, Hansen KP, Caldwell EE, and Linhardt RJ
- Subjects
- Carbohydrate Sequence, Complement Inactivator Proteins chemical synthesis, Complement Inactivator Proteins pharmacology, Factor Xa Inhibitors, Glycosaminoglycans chemistry, Glycosaminoglycans isolation & purification, Glycosaminoglycans pharmacology, Magnetic Resonance Spectroscopy, Molecular Sequence Data, Molecular Structure, Prothrombin antagonists & inhibitors, Sulfonamides pharmacology, Chondroitin Sulfates metabolism, Chondroitin Sulfates pharmacology, Dermatan Sulfate metabolism, Dermatan Sulfate pharmacology, Sulfonamides chemical synthesis
- Published
- 1996
- Full Text
- View/download PDF
48. Fluticasone propionate aqueous nasal spray compared with terfenadine tablets in the treatment of seasonal allergic rhinitis.
- Author
-
Bronsky EA, Dockhorn RJ, Meltzer EO, Shapiro G, Boltansky H, LaForce C, Ransom J, Weiler JM, Blumenthal M, Weakley S, Wisniewski M, Field E, and Rogenes P
- Subjects
- Administration, Intranasal, Administration, Oral, Adolescent, Adult, Aged, Androstadienes administration & dosage, Androstadienes adverse effects, Anti-Allergic Agents administration & dosage, Anti-Allergic Agents adverse effects, Child, Double-Blind Method, Female, Fluticasone, Humans, Male, Middle Aged, Nebulizers and Vaporizers, Rhinitis, Allergic, Seasonal complications, Tablets, Terfenadine administration & dosage, Androstadienes therapeutic use, Anti-Allergic Agents therapeutic use, Rhinitis, Allergic, Seasonal drug therapy, Terfenadine therapeutic use
- Abstract
Background: Comparative studies with topical corticosteroids and antihistamines for treatment of allergic rhinitis have not always demonstrated clear distinctions between the two on the basis of therapeutic efficacy., Objective: This study was designed to compare the efficacy and tolerability of fluticasone propionate aqueous nasal spray with those of terfenadine in the treatment of seasonal allergic rhinitis., Methods: Three hundred forty-eight patients with allergic rhinitis were given fluticasone propionate aqueous nasal spray (200 micrograms once daily), terfenadine tablets (60 mg twice daily), or placebo for 4 weeks in a multicenter, randomized, double-blind, double-dummy, parallel-group study., Results: Clinician-rated total nasal symptom scores after 1, 2, 3, and 4 weeks of therapy and patient-rated total nasal symptom scores throughout treatment were significantly (p <0.05) lower in the fluticasone propionate group compared with the terfenadine group or the placebo group. Terfenadine was not statistically different from placebo on the basis of clinician-related nasal symptom scores, except for sneezing. Total nasal airflow, measured by rhinomanometry, significantly (p <0.05) improved in the fluticasone propionate group compared with the terfenadine group or the placebo group. More fluticasone propionate-treated patients compared with placebo-treated patients had reduced nasal mucosal eosinophil counts after 4 weeks of therapy (p <0.05). No serious or unusual drug-related adverse events were reported. Morning plasma cortisol concentrations after 4 weeks of therapy did not differ among groups., Conclusion: Fluticasone propionate aqueous nasal spray is more effective than terfenadine tablets for treatment of seasonal allergic rhinitis.
- Published
- 1996
- Full Text
- View/download PDF
49. Importance of specific amino acids in protein binding sites for heparin and heparan sulfate.
- Author
-
Caldwell EE, Nadkarni VD, Fromm JR, Linhardt RJ, and Weiler JM
- Subjects
- Amino Acid Sequence, Binding Sites, Carbohydrate Sequence, Chemical Fractionation, Molecular Sequence Data, Protein Binding, Amino Acids chemistry, Heparitin Sulfate chemistry, Receptors, Cell Surface chemistry
- Abstract
Heparin and heparan sulfate bind a variety of proteins and peptides to regulate many biological activities. Past studies have examined a limited number of established heparin binding sites and have focused on basic amino acids when modeling binding site structural motifs. This study examines the prevalence of individual amino acids in peptides binding to heparin or heparan sulfate. A 7-mer random peptide library was synthesized using the 20 common amino acids. This 7-mer library was affinity separated using both heparin and heparan sulfate-Sepharose. Bound peptide populations were eluted with a salt step gradient (pH 7) and analysed for amino acid composition. Peptides released from heparin-Sepharose by 0.3 M NaCl were enriched in arginine, lysine, glycine and serine; and depleted in methionine and phenylalanine. In contrast, peptides released from heparan sulfate-Sepharose were enriched in arginine, glycine, serine, and proline (at 0.15 M NaCl). These peptides were depleted in histidine, isoleucine, methionine (not detectable) and phenylalanine. In the heparin binding sites of proteins, which have been published, the enriched amino acids were arginine, lysine and tyrosine. Depleted amino acids include aspartic acid, glutamic acid, glutamine, alanine, glycine, phenylalanine, serine, threonine and valine. This study demonstrates that heparin and heparan sulfate bind different populations of peptide sequences. The differences in amino acid composition indicate that the positive charge density and spacing requirements differ for peptides binding these two glycosaminoglycans.
- Published
- 1996
- Full Text
- View/download PDF
50. Comparative outdoor study of the efficacy, onset and duration of action, and safety of cetirizine, loratadine, and placebo for seasonal allergic rhinitis.
- Author
-
Meltzer EO, Weiler JM, and Widlitz MD
- Subjects
- Adolescent, Adult, Cetirizine adverse effects, Child, Double-Blind Method, Female, Humans, Loratadine adverse effects, Male, Middle Aged, Placebos, Pollen, Rhinitis, Allergic, Seasonal physiopathology, Severity of Illness Index, Time Factors, Cetirizine therapeutic use, Loratadine therapeutic use, Rhinitis, Allergic, Seasonal drug therapy
- Abstract
Background: Cetirizine, a new once-daily highly specific H1-antagonist, has been shown in conventional studies to be efficacious in the treatment of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria., Objective: The efficacy, duration and onset of action, and safety of cetirizine, 10 mg once daily, was compared with that of loratadine, 10 mg once daily, and placebo in a field study of patients with seasonal allergic rhinitis., Methods: This was a randomized, double-blind, parallel, double-dummy study conducted over 2 days in spring allergy season at outdoor parks in San Diego and Iowa City. Study medication was administered at 10:00 AM on both days. After screening, eligible patients completed rhinitis symptom diaries in the park hourly from 7:30 to 9:30 AM (baseline); at 10:30 AM and hourly from 11:00 AM to 4:00 PM (period I); at 6:00, 8:00, and 10:00 PM at home (period II); and the next day in the park hourly from 8:00 to 10:00 AM (period III), and from 11:00 AM to 4:00 PM (period IV). Major and total symptom complex scores, global efficacy and overall satisfaction, and adverse events were assessed., Results: Of the 279 patients (140 men and 139 women; mean age, 29 years) randomized to treatment, 278 were included in the efficacy analysis. Cetirizine produced significantly greater mean reductions than loratadine or placebo in major symptom complex severity scores at all periods (p < or = 0.05), except period I for placebo. Cetirizine also produced mean reductions in total symptom complex severity scores that were superior to loratadine at every evaluation period (p < 0.05) and were statistically different from placebo at period II (p < 0.01). A rapid onset of action was observed with cetirizine, as was a better response pattern in the patient global assessment of efficacy compared with loratadine. Study medications were well tolerated; no patient stopped treatment because of side effects. The incidence of somnolence with cetirizine was 13% versus 2% with placebo (p < 0.05); headache occurred more frequently with loratadine (23%) than with cetirizine (11%, p = 0.03)., Conclusions: Cetirizine relieved rhinitis symptoms more effectively and quickly than loratadine and placebo in this field study of seasonal allergic rhinitis. Both active agents were generally well tolerated.
- Published
- 1996
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.